$VC

PYNNONEN BRETT D sold $600K of VC

PYNNONEN BRETT D (SVP & Chief Legal Officer) sold 5,000 shares of VISTEON CORP (VC) at $120.00 ($0.60M total) on 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · PYNNONEN BRETT D
Published Jun 9, 2026, 8:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 8:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VC
Neutral
high confidence
Mentioned
$VC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VCNeutralLow
01

Why it matters

This adds incremental transparency on insider activity but does not introduce new information about Visteon’s business, financial performance, or external catalysts.

02

Market read

Traders may treat it as routine insider liquidity rather than a fundamental catalyst.

03

What to watch

The article provides only the sale details; it does not include context like prior buys/sales cadence, option exercises, or whether other insiders are transacting.

Relevance 4/10Novelty 5/10Timing: Filed June 9; sale executed June 5.

Background

The article is an SEC Form 4 disclosure of an insider’s open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$VCNeutralHigh confidence
Context

Visteon’s SVP & Chief Legal Officer sold 5,000 shares (~$600K) via an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, and it does not disclose new company fundamentals, guidance, or regulatory/contract events.

Market effects

No sector read-through; this is an individual insider transaction without operational or regulatory implications.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with management’s private view of risk; traders may still monitor for follow-on sales.

Key entities

  • VISTEON CORP

    Company whose insider transaction is disclosed on SEC Form 4.

  • PYNNONEN BRETT D

    SVP & Chief Legal Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Visteon Corporation Q3 2026 Earnings Call Summary

Visteon Corporation reported Q3 2026 earnings, highlighting 10 percentage points of market outperformance despite a 5% decline in vehicle production. The company addressed $77 million in warranty charges and managed inflation in PCBs. For 2027, Visteon anticipates $500 million in incremental costs and aims to maintain EBITDA targets through customer recoveries. China sales are expected to grow in Q4 2026, driven by high-performance compute launches.

Med

Visteon (VC) Q3 2026 Earnings Call Transcript

Visteon (VC) reported Q3 2026 earnings, highlighting a $200M share repurchase and sales growth despite market challenges. Sales grew in Americas, Europe, and Asia (excluding China), with China sales expected to recover in Q4. The company launched 21 new products, including high-value cockpit technologies, and secured $1B in new business bookings, targeting $6B for the year. Strategic wins include programs with Toyota, Maruti Suzuki, and Tata Motors.

$VCMedAI 8/10

What Visteon (VC) Said on Its Q3 Earnings Call

Visteon (VC) reported Q3 earnings, noting regional sales trends and product launches. Sales rose 14% in Asia excluding China, but faced challenges in the Americas and China. The company expects China sales to grow in Q4 with new launches. Visteon launched 21 products and booked $1B in new business, maintaining its $6B annual target. It updated guidance, raising full-year sales to $3.8B-$3.85B but lowering adjusted EBITDA to $370M-$410M. Q4 sales are expected to be $940M, flat YoY.